TG Therapeutics, Inc. (TGTX) shares rallied sharply Tuesday after the biotech company delivered preliminary fiscal 2025 results that demonstrated impressive growth for its multiple sclerosis treatment BRIUMVI.

BRIUMVI Powers Revenue Growth

The numbers tell a compelling story. TG Therapeutics reported preliminary total global revenue of approximately $616 million for full-year 2025. Breaking that down further, BRIUMVI generated approximately $182 million in U.S. net product revenue during the fourth quarter alone, bringing the full-year total to roughly $594 million. Worth noting: these figures are unaudited and subject to final closing procedures, so consider them preliminary for now.

But here's what really caught investors' attention: the company's outlook for 2026. Management is targeting total global revenue between $875 million and $900 million, representing substantial year-over-year growth. Within that forecast, BRIUMVI U.S. net product revenue is expected to hit $825 million to $850 million. That's confidence.

Of course, growth doesn't come free. The company projected full-year 2026 operating expenses of approximately $350 million, excluding non-cash compensation. Add another $100 million in expenses related to subcutaneous BRIUMVI inventory build and secondary manufacturer start-up costs. These investments signal the company is preparing for expansion rather than just maintaining the status quo.

Pipeline Milestones on the Horizon

Beyond the revenue story, TG Therapeutics outlined several development milestones for 2026 that should keep investors watching closely. The company expects mid-year topline data from the ENHANCE trial, which is evaluating consolidated IV dosing of BRIUMVI. In the second half of the year, preliminary Phase 1 data for azer-cel in progressive multiple sclerosis should arrive. And finally, topline data for subcutaneous BRIUMVI is anticipated around year-end 2026 or early 2027.

Technical Picture Tells a Different Story

While the fundamental news sparked a rally, the technical setup for TGTX remains somewhat troubled. The stock is trading 1.7% above its 20-day simple moving average, which sounds fine until you look at the longer timeframes. It's 1.6% below the 50-day SMA, 5% below the 100-day SMA, and 10.3% below the 200-day SMA. That pattern suggests an underlying bearish trend that one good earnings report might not completely reverse.

The RSI currently sits at 34.82, hovering in neutral territory but leaning toward oversold. That could indicate room for a bounce if buying interest continues. However, the MACD remains below its signal line, pointing to ongoing bearish pressure that could cap upside momentum.

Key levels to watch: support sits at $30.00, while resistance appears around $34.00. If the stock can't hold support, further downside could follow. Breaking through resistance, on the other hand, might signal a genuine trend reversal rather than just a relief rally.

One concerning signal came back in August when the stock experienced a death cross—the 50-day SMA crossing below the 200-day SMA. That classic bearish indicator reinforces the current downward momentum and suggests caution is warranted.

Over the past year, TGTX has declined 6.29%, reflecting sustained challenges. The stock is positioned at just 25.1% of its 52-week range, meaning it's much closer to its lows than its highs. That positioning indicates weaker market sentiment that predates this week's positive news.

The technical setup suggests traders should watch those support and resistance levels carefully. The fundamental story is improving, but the technical picture needs to catch up before the all-clear signal sounds.

TGTX Price Action: At the time of writing, TG Therapeutics shares are trading 11.23% higher at $31.00.